SMARCA2 and cancer: In contrast to a previously described SMARCA2/4 ATPase inhibitor14 and PROTAC26, these findings provide the an example of a selective SMARCA2 targeting agent and provide pharmacologic support of this previously defined synthetic lethality in SMARCA4mut cancers.